<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004141</url>
  </required_header>
  <id_info>
    <org_study_id>9372</org_study_id>
    <secondary_id>UCCRC-9372</secondary_id>
    <secondary_id>UCCRC-CTRC-9821</secondary_id>
    <secondary_id>NCI-G99-1615</secondary_id>
    <nct_id>NCT00004141</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Plus Biological Therapy in Treating Patients With Metastatic Melanoma</brief_title>
  <official_title>Phase II Study of Outpatient CDDP and DTIC Followed by GM-CSF, IFN-a2b, and IL-2 in Patients With Advanced Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Biological therapies use different ways to stimulate the immune&#xD;
      system and stop cancer cell from growing. Combining more than one drug with different types&#xD;
      of biological therapies may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus&#xD;
      biological therapy in treating patients who have metastatic melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the toxicity of cisplatin and dacarbazine followed by sargramostim (GM-CSF),&#xD;
           interferon alfa, and interleukin-2 in patients with metastatic melanoma.&#xD;
&#xD;
        -  Determine the objective response rate, relapse free survival, and overall survival of&#xD;
           these patients on this regimen.&#xD;
&#xD;
      OUTLINE: Patients receive cisplatin IV over 1 hour and dacarbazine IV over 30-60 minutes&#xD;
      sequentially on day 1, followed by sargramostim (GM-CSF) subcutaneously (SC) on days 2-7,&#xD;
      interleukin-2 SC on days 8-14, and interferon alfa SC on days 8, 10, 12, and 14. Treatment&#xD;
      repeats every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 8 weeks until disease progression, and then every 8-12 weeks&#xD;
      thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 15-45 patients will be accrued for this study within 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1998</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <primary_completion_date type="Actual">January 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Melanoma (Skin)</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CDDP (75 mg/m2) and DTIC (660 mg/m2) will be administered sequentially by intravenous infusion in day 1. Subsequently, GM-CSF (450 mg/ m2) will be administered SC days 2-7; IL-2 (11 MU daily) will be given SC days 8-14, and IFN-2b (9 MU) will be given SC days 8, 10, 12, and 14.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>CDDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dacarbazine</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>DTIC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granulocyte-macrophage colony-stimulating factor</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>GM-CSF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed metastatic melanoma&#xD;
&#xD;
               -  Stage III with intransit metastases&#xD;
&#xD;
               -  Stage IV&#xD;
&#xD;
          -  No uncontrolled brain metastases by CT scan&#xD;
&#xD;
          -  No clinically significant ascites or pleural effusions&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 10 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 9.5 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  SGOT no greater than 4 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance at least 70 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No clinically significant cardiac disease on EKG, echocardiogram, or MUGA scan&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No clinically significant pulmonary disease on chest x-ray&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No significant thyroid dysfunction&#xD;
&#xD;
          -  No concurrent severe infection&#xD;
&#xD;
          -  No other medical or psychiatric condition that would interfere with compliance&#xD;
&#xD;
          -  No second malignancy within the past 5 years, except:&#xD;
&#xD;
               -  Localized nonmelanomatous skin cancer&#xD;
&#xD;
               -  Carcinoma in situ of the cervix&#xD;
&#xD;
               -  Grade 1 Ta bladder cancer&#xD;
&#xD;
          -  Suspected hearing deficits must undergo audiologic testing&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No more than one prior immunotherapy regimen&#xD;
&#xD;
          -  At least 4 weeks since prior immunotherapy&#xD;
&#xD;
          -  Adjuvant interferon alfa before relapse allowed&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No more than one prior chemotherapy regimen&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks since nitrosoureas)&#xD;
&#xD;
          -  No concurrent cyclophosphamide&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent corticosteroids or cyclosporine A&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 2 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 3 weeks since major surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent immunosuppressive drugs&#xD;
&#xD;
          -  No other concurrent investigational antineoplastic drugs&#xD;
&#xD;
          -  Concurrent thyroid replacement therapy allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas F. Gajewski, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>December 10, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 4, 2013</last_update_submitted>
  <last_update_submitted_qc>September 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Molgramostim</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

